These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
163 related articles for article (PubMed ID: 36521526)
1. Neoadjuvant Immunotherapy in Oncogene-Positive Non-Small Cell Lung Cancer: A Multicenter Study. Zhao ZR; Lin ZC; Shen JF; Xie ZH; Jiang L Ann Thorac Surg; 2023 Oct; 116(4):703-710. PubMed ID: 36521526 [TBL] [Abstract][Full Text] [Related]
2. Neoadjuvant PD-(L)1 blockade plus platinum-based chemotherapy for potentially resectable oncogene-positive non-small cell lung cancer. Zhang X; Zhang H; Hou F; Fang T; Zhang C; Wang H; Song S; Lan H; Wang Y; Hou H World J Surg Oncol; 2024 Jun; 22(1):159. PubMed ID: 38890622 [TBL] [Abstract][Full Text] [Related]
3. Atezolizumab with or without bevacizumab and platinum-pemetrexed in patients with stage IIIB/IV non-squamous non-small cell lung cancer with EGFR mutation, ALK rearrangement or ROS1 fusion progressing after targeted therapies: A multicentre phase II open-label non-randomised study GFPC 06-2018. Bylicki O; Tomasini P; Radj G; Guisier F; Monnet I; Ricordel C; Bigay-Game L; Geier M; Chouaid C; Daniel C; Swalduz A; Toffart AC; Doubre H; Peloni JM; Moreau D; Subtil F; Grellard JM; Castera M; Clarisse B; Martins-Lavinas PH; Decroisette C; Greillier L; Eur J Cancer; 2023 Apr; 183():38-48. PubMed ID: 36801605 [TBL] [Abstract][Full Text] [Related]
4. The impact of oncogenic driver mutations on neoadjuvant immunotherapy outcomes in patients with resectable non-small cell lung cancer. Shen Z; Teng M; Han L; Bian D; Zhang J; Zhu X; Qing Y; Hu S; Chen Y; Yao W; Yu H; Zhang L; Zhang P Cancer Immunol Immunother; 2023 Dec; 72(12):4235-4247. PubMed ID: 37932425 [TBL] [Abstract][Full Text] [Related]
5. Interim analysis of the efficiency and safety of neoadjuvant PD-1 inhibitor (sintilimab) combined with chemotherapy (nab-paclitaxel and carboplatin) in potentially resectable stage IIIA/IIIB non-small cell lung cancer: a single-arm, phase 2 trial. Sun C; Liu Y; Zhang P; Wang X; Xu Y; Lin X; Ma X; Guo Y; Qiu S; Shao G; Yang Z; Ma K J Cancer Res Clin Oncol; 2023 Feb; 149(2):819-831. PubMed ID: 35192053 [TBL] [Abstract][Full Text] [Related]
6. Clinical outcomes associated with neoadjuvant therapy for the treatment of resectable non-small cell lung cancer in real-world practice. Huang X; Pang G; Mao Z; Li B; Teng Z; Yang Y; Qiu Z; Chen X; Wang P Clin Respir J; 2024 May; 18(5):e13761. PubMed ID: 38693705 [TBL] [Abstract][Full Text] [Related]
7. Phase 2 trial of neoadjuvant toripalimab with chemotherapy for resectable stage III non-small-cell lung cancer. Zhao ZR; Yang CP; Chen S; Yu H; Lin YB; Lin YB; Qi H; Jin JT; Lian SS; Wang YZ; You JQ; Zhai WY; Long H Oncoimmunology; 2021; 10(1):1996000. PubMed ID: 34712513 [TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of neoadjuvant immunotherapy plus chemotherapy followed by adjuvant immunotherapy in resectable non-small cell lung cancer: a meta-analysis of phase 3 clinical trials. Zhang W; Liang Z; Zhao Y; Li Y; Chen T; Li W; Chen Y; Wu P; Zhang H; Fang C; Li L Front Immunol; 2024; 15():1359302. PubMed ID: 38646542 [TBL] [Abstract][Full Text] [Related]
9. SAKK 16/14: Durvalumab in Addition to Neoadjuvant Chemotherapy in Patients With Stage IIIA(N2) Non-Small-Cell Lung Cancer-A Multicenter Single-Arm Phase II Trial. Rothschild SI; Zippelius A; Eboulet EI; Savic Prince S; Betticher D; Bettini A; Früh M; Joerger M; Lardinois D; Gelpke H; Mauti LA; Britschgi C; Weder W; Peters S; Mark M; Cathomas R; Ochsenbein AF; Janthur WD; Waibel C; Mach N; Froesch P; Buess M; Bohanes P; Godar G; Rusterholz C; Gonzalez M; Pless M; J Clin Oncol; 2021 Sep; 39(26):2872-2880. PubMed ID: 34251873 [TBL] [Abstract][Full Text] [Related]
10. Treatment patterns and clinical outcomes of patients with resectable non-small cell lung cancer receiving neoadjuvant immunochemotherapy: A large-scale, multicenter, real-world study (NeoR-World). Yang Z; Wang S; Yang H; Jiang Y; Zhu L; Zheng B; Fu H; Ma J; Xie H; Wang Z; He H; Xia C; Li R; Xu J; Han J; Huang X; Li Y; Zhao B; Ni C; Xing H; Chen Y; Wang J; Jiang Y; Song Y; Mao Y; Chen C; Yao F; Zhang G; Hu J; Xue Q; Gao S; He J; J Thorac Cardiovasc Surg; 2024 Oct; 168(4):1245-1258.e17. PubMed ID: 38342430 [TBL] [Abstract][Full Text] [Related]
11. Surgical results of the Lung Cancer Mutation Consortium 3 trial: A phase II multicenter single-arm study to investigate the efficacy and safety of atezolizumab as neoadjuvant therapy in patients with stages IB-select IIIB resectable non-small cell lung cancer. Rusch VW; Nicholas A; Patterson GA; Waqar SN; Toloza EM; Haura EB; Raz DJ; Reckamp KL; Merritt RE; Owen DH; Finley DJ; McNamee CJ; Blasberg JD; Garon EB; Mitchell JD; Doebele RC; Baciewicz F; Nagasaka M; Pass HI; Schulze K; Johnson A; Bunn PA; Johnson BE; Kris MG; Kwiatkowski DJ; Wistuba II; Chaft JE; Carbone DP; Lee JM J Thorac Cardiovasc Surg; 2023 Mar; 165(3):828-839.e5. PubMed ID: 36369159 [TBL] [Abstract][Full Text] [Related]
12. Efficacy and Safety of the PD-1 Inhibitor Combined with Albumin-Bound Paclitaxel and Nedaplatin in Preoperative Neoadjuvant Therapy of Unresectable Stage III Lung Squamous Cell Carcinoma. Xu H; Wang W; Yin J; Song C; Li L; Sun Z Drug Des Devel Ther; 2022; 16():4269-4277. PubMed ID: 36540715 [TBL] [Abstract][Full Text] [Related]
13. Neoadjuvant chemotherapy and Avelumab in early stage resectable nonsmall cell lung cancer. Tfayli A; Al Assaad M; Fakhri G; Akel R; Atwi H; Ghanem H; El Karak F; Farhat F; Al Rabi K; Sfeir P; Youssef P; Mansour Z; Assi H; Haidar M; Abi Ghanem A; Khalifeh I; Boulos F; Mahfouz R; Youssef B; Zeidan Y; Bejjany R; Khuri F Cancer Med; 2020 Nov; 9(22):8406-8411. PubMed ID: 32991781 [TBL] [Abstract][Full Text] [Related]
14. Oncogene-specific differences in tumor mutational burden, PD-L1 expression, and outcomes from immunotherapy in non-small cell lung cancer. Negrao MV; Skoulidis F; Montesion M; Schulze K; Bara I; Shen V; Xu H; Hu S; Sui D; Elamin YY; Le X; Goldberg ME; Murugesan K; Wu CJ; Zhang J; Barreto DS; Robichaux JP; Reuben A; Cascone T; Gay CM; Mitchell KG; Hong L; Rinsurongkawong W; Roth JA; Swisher SG; Lee J; Tsao A; Papadimitrakopoulou V; Gibbons DL; Glisson BS; Singal G; Miller VA; Alexander B; Frampton G; Albacker LA; Shames D; Zhang J; Heymach JV J Immunother Cancer; 2021 Aug; 9(8):. PubMed ID: 34376553 [TBL] [Abstract][Full Text] [Related]
15. The role of docetaxel (Taxotere) as a single agent or in combination before local treatment of non-small cell lung cancer. Harper P Semin Oncol; 1997 Aug; 24(4 Suppl 14):S14-30-S14-32. PubMed ID: 9335522 [TBL] [Abstract][Full Text] [Related]
16. Neoadjuvant atezolizumab and chemotherapy in patients with resectable non-small-cell lung cancer: an open-label, multicentre, single-arm, phase 2 trial. Shu CA; Gainor JF; Awad MM; Chiuzan C; Grigg CM; Pabani A; Garofano RF; Stoopler MB; Cheng SK; White A; Lanuti M; D'Ovidio F; Bacchetta M; Sonett JR; Saqi A; Rizvi NA Lancet Oncol; 2020 Jun; 21(6):786-795. PubMed ID: 32386568 [TBL] [Abstract][Full Text] [Related]
17. Gefitinib as neoadjuvant therapy for resectable stage II-IIIA non-small cell lung cancer: A phase II study. Zhang Y; Fu F; Hu H; Wang S; Li Y; Hu H; Chen H J Thorac Cardiovasc Surg; 2021 Feb; 161(2):434-442.e2. PubMed ID: 32340810 [TBL] [Abstract][Full Text] [Related]
18. Efficiency and safety of neoadjuvant PD-1 inhibitor (sintilimab) combined with chemotherapy in potentially resectable stage IIIA/IIIB non-small cell lung cancer: Neo-Pre-IC, a single-arm phase 2 trial. Sun C; Wang X; Xu Y; Shao G; Chen X; Liu Y; Zhang P; Lin X; Ma X; Qiu S; He H; Yang Z; Ma K EClinicalMedicine; 2024 Feb; 68():102422. PubMed ID: 38304743 [TBL] [Abstract][Full Text] [Related]
19. ROS1 Fusions Rarely Overlap with Other Oncogenic Drivers in Non-Small Cell Lung Cancer. Lin JJ; Ritterhouse LL; Ali SM; Bailey M; Schrock AB; Gainor JF; Ferris LA; Mino-Kenudson M; Miller VA; Iafrate AJ; Lennerz JK; Shaw AT J Thorac Oncol; 2017 May; 12(5):872-877. PubMed ID: 28088512 [TBL] [Abstract][Full Text] [Related]
20. [Preliminary Efficacy Evaluation of Neoadjuvant Immunotherapy Combined with Chemotherapy in Resectable Non-small Cell Lung Cancer]. Zhou S; Hao X; Yu D; Liu S; Cao X; Su C; Song X; Xiao N; Li Y; Yang W; Zhao D; Wang J; Liu Z; Xu S Zhongguo Fei Ai Za Zhi; 2021 Jun; 24(6):420-425. PubMed ID: 34024062 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]